Brivanib
- Generic Name
- Brivanib
- Drug Type
- Small Molecule
- Chemical Formula
- C19H19FN4O3
- CAS Number
- 649735-46-6
- Unique Ingredient Identifier
- DDU33B674I
- Background
Brivanib is under investigation for the treatment of HepatoCellular Carcinoma. Brivanib has been investigated for the treatment of Solid Tumors, Hepato Cellular Carcinoma (HCC), and Metastatic Colorectal Cancer (MCRC).
Phase I/II Combination With Irinotecan- Erbitux
- Conditions
- Metastatic Colorectal Cancer (MCRC)
- Interventions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 38
- Registration Number
- NCT00594984
- Locations
- πΊπΈ
Usc/Norris Comprehensive Cancer Center Hospital, Los Angeles, California, United States
πΊπΈUsc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈWashington University, Saint Louis, Missouri, United States
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 29
- Registration Number
- NCT00437437
- Locations
- πΊπΈ
Dana-Farber Harvard Cancer Care, Boston, Massachusetts, United States
πΊπΈWayne State University, Detroit, Michigan, United States
πΊπΈDuke University Medical Center-Dept Of Medicine, Durham, North Carolina, United States
A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT00437424
- Locations
- πͺπΈ
Local Institution, Sevilla, Spain
πΊπΈUniversity Of Alabama At Birmingham, Birmingham, Alabama, United States
πΊπΈUsc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
- Conditions
- Tumors
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2009-01-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4
- Registration Number
- NCT00435669
- Locations
- πΊπΈ
Cleveland Clinic Foundation, Cleveland, Ohio, United States
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 13
- Registration Number
- NCT00390936
- Locations
- π―π΅
Local Institution, Sunto-Gun, Shizuoka, Japan
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
- First Posted Date
- 2006-07-21
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 137
- Registration Number
- NCT00355238
- Locations
- πΊπΈ
Univ Of Texas Southwestern, Dallas, Texas, United States
πΊπΈNorthwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
πΊπΈMD Anderson Cancer Center, Houston, Texas, United States
BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 62
- Registration Number
- NCT00207051
- Locations
- πΊπΈ
Karmanos Cancer Institute, Detroit, Michigan, United States
πΊπΈH. Lee Moffitt Cancer Center, Tampa, Florida, United States
πΊπΈUsc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT00207103
- Locations
- πΊπΈ
Premiere Oncology, Santa Monica, California, United States
πΊπΈUniversity Of Wisconsin Comprehensive Center, Madison, Wisconsin, United States
π¬π§Local Institution, Manchester, Greater Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.